AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOPHARMA, INC. on January 23, 2023, with the earliest event reported on that date. The Company is incorporated in Delaware and its common stock trades on The NASDAQ Stock Market LLC under the symbol "AYTU".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory compliance rather than financial performance metrics.
Material Changes
On January 23, 2023, the Company received notification from the Nasdaq Staff that it regained compliance with Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per share. Consequently, the Nasdaq Staff closed the matter regarding the Company's listing status.
Outlook, Risks, and Management Commentary
Management confirmed that the Company is now fully compliant with all Nasdaq listing rules. A press release titled "Aytu BioPharma Regains Nasdaq Bid Price Compliance" was issued on January 25, 2023, and is attached as Exhibit 99.1. The filing does not disclose new risks, contingencies, or unusual items beyond the resolution of the bid price deficiency.
Key Facts for Investor Verification
- Verify the current trading price of AYTU stock to ensure it remains above the $1.00 minimum bid price threshold.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the Company's capital structure or future plans.
- Confirm the Company's continued compliance with other Nasdaq listing requirements in subsequent filings.